Aclarion, Inc. (ACON) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Aclarion, Inc.'s filing signal turned positive.

Aclarion, Inc. is a healthcare technology company specializing in Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments, primarily targeting the $134.5 billion U.S. low back and neck pain market. The company's core technology, NOCISCAN(R), analyzes the chemical makeup of intervertebral discs to identify biomarkers associated with pain, offering a non-invasive alternative to traditional diagnostic methods like Provocation Discogram tests. Aclarion's strategy focuses on improving surgical outcomes for discogenic low back pain by assisting surgeons in determining optimal procedures, with plans to expand its technology's application to conservative therapies and neck pain populations. The company is actively pursuing payer contracts and conversion of its Category III CPT codes to Category I codes to drive broader adoption and reimbursement.

Aclarion generates revenue primarily through the sale of its NOCISCAN(R) reports to medical professionals. Revenue is recognized upon the delivery of these reports, with a significant portion currently coming from the United Kingdom market due to local coverage decisions, and from direct patient payments in the United States.